Maintenance Treatment with Letrozole Versus Placebo for Estrogen-Receptor Positive Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer A Phase III Randomized Double-Blind Study
Led by Swiss GO Trial Group · Updated on 2025-09-29
540
Participants Needed
53
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the addition of letrozole, an aromatase inhibitor, to the standard maintenance therapy in women diagnosed with estrogen-receptor ER positive epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer. This study focuses on both low and high grade serous or endometrioid ovarian cancers at FIGO Stage II-IV, whose cancer has not progressed after primary surgery and platinum-based chemotherapy. The main goal is to determine if letrozole can increase progression-free survival compared to the current standard maintenance treatment with placebo.
Participants are randomly assigned to receive either letrozole 2.5 mg daily or a placebo tablet once daily for up to five years or until toxicity symptoms or disease progression occur. This randomized, double-blinded, multicenter phase III trial involves 540 eligible women who will be monitored throughout the treatment period. The study also includes a sub-study focusing on low grade ovarian cancer LOGOS. Treatment adherence and tolerability will be assessed during regular visits.
Participants will undergo health assessments including blood tests, physical and gynecological exams, and possibly imaging during routine follow-ups every 12 weeks for the first two years, then every 24 weeks for three additional years. Quality of life will be evaluated using specific questionnaires, and participants will wear an activity tracker for one week before visits. Researchers will measure progression-free survival as the primary outcome and also evaluate overall survival, time to next treatment, and quality-adjusted survival. Follow-up data will be collected for up to 12 years, including up to seven years after treatment ends to monitor long-term outcomes.
CONDITIONS
Brief Title
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Research Team
M
McLaughlin, PhD
V
Vogel, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Willing and able to attend visits and understand study procedures
Newly diagnosed FIGO Stage II to IV low or high grade serous or endometrioid epithelial ovarian, fallopian tube, or peritoneal cancer
(Interval-) debulking surgery performed
ECOG Performance Status 0-2
Signed informed consent forms
Available paraffin-embedded tissue or cell block from ascites
Estrogen receptor expression of 1% or higher
Completed at least 4 cycles of platinum-based chemotherapy
Negative serum pregnancy test if of childbearing potential and sterilized by surgery or radiation prior to intervention
You will not qualify if you...
Progressive disease at the end of adjuvant treatment
Women of childbearing potential not surgically or radiation sterilized prior to intervention
Pregnant or lactating women
Other malignancy within the last 5 years affecting prognosis
Fewer than 4 cycles of chemotherapy completed
Contraindications to endocrine therapy
Inability or unwillingness to swallow tablets
Known intolerance to galactose, lactase deficiency, or glucose-galactose malabsorption
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 5 years
Participants receive maintenance therapy with either letrozole or placebo for up to 5 years or until symptoms of toxicity or disease progression.
Routine follow-up visits every 12 weeks for the first 2 years, then every 24 weeks for the next 3 years
Follow-up
Duration - Up to 7 years
After maintenance treatment ends, participants are followed for survival outcomes and quality of life for up to 7 additional years.
Visits occur during routine ovarian cancer follow-up care; exact schedule may vary
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 1 Study of BMS-986463 Drug for Treating Advanced High-grade Serous Ovarian, Uterine Serous, and Non-small Cell Lung Cancers
Three-Part Study of Sofetabart Mipitecan Compared to Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer and Sofetabart Mipitecan Plus Bevacizumab Compared to Platinum Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Phase IIb Study of BP1001-A Alone and With Paclitaxel in Adults With Advanced or Recurrent Solid Tumors
Phase 2 Study to Detect Ovarian Cancer Using DNA from Uterine Lavage and Blood Proteins
Building a Clinical and Biological Database for Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancers
Collecting Blood and Tissue Samples Alongside Clinical Data
Comparing 20% Albumin Plus Ringer Lactate Versus Ringer Lactate Alone
for Fluid Therapy During Cytoreductive Surgery with Hyperthermic
Intraperitoneal Chemotherapy
Maintenance Treatment with Letrozole Versus Placebo for Estrogen-Receptor Positive Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer A Phase III Randomized Double-Blind Study
Pilot Randomized Trial Comparing Robotic Versus Open Surgery for Women with Complex Pelvic Adnexal Masses 8 cm or Smaller
OV Precision Trial Evaluating Personalized Molecular Tumor Board Therapy Versus Standard Chemotherapy for Advanced Ovarian Cancer
Study of Tranexamic Acid Given by Intravenous or Intramuscular Injection
in Women Aged 20 to 64 With Advanced Ovarian Cancer Undergoing Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
Pamela M J McLaughlin, Maximilian Klar, Tibor A Zwimpfer...